Last updated: January 7, 2022
Sponsor: University of Oulu
Overall Status: Active - Enrolling
Phase
2
Condition
Diabetes Prevention
Diabetes Mellitus, Type 1
Diabetes And Hypertension
Treatment
N/AClinical Study ID
NCT02611232
LiraAAB18-30
2014-003667-37
U1111-1176-6062
3-SRA-2014-301-M-R
Ages 18-30 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- 18-30 years of age
- positive for at least 2 biochemical islet autoantibodies
- have normal glucose tolerance in OGTT
- are not pregnant
Exclusion
Exclusion Criteria:
- allergic to liraglutide or other ingredients of Victoza®
- Type 1 diabetes
- diabetic ketoacidosis
- previous treatment in the last three months with any antidiabetic medication
- impaired liver or kidney function or on dialysis
- severe heart failure
- severe stomach or gut problem resulting in gastroparesis, or inflammatory boweldisease
- past or current history of pancreatitis
- serum calcitonin value above normal (>50 ng/l or ≥3.4pmol/l)
- presence of any chronic metabolic, hematologic or malignant disease
- obesity BMI ≥30
- pregnant females and females of childbearing potential who are not using adequatecontraceptive methods.
- breast-feeding
Study Design
Total Participants: 42
Study Start date:
December 01, 2015
Estimated Completion Date:
June 30, 2024
Connect with a study center
University of Oulu and Oulu University Hospital
Oulu, 90029
FinlandSite Not Available
University of Tampere and Tampere University Hospital
Tampere, 33521
FinlandSite Not Available
University of Turku and Turku University Hospital
Turku, 20520
FinlandSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.